Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies : Episode 1
Indication and Practical Utilization of IV and Subcutaneous Biologics
Jill Zouzoulas, MD, FACR, opens a discussion highlighting use of biologics in her practice.
Now Viewing
EP: 1.Indication and Practical Utilization of IV and Subcutaneous Biologics
EP: 2.Key Consideration and Concerns Around IV and Subcutaneous Biologic Use
EP: 3.Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
EP: 4.Key Patient Factors in Determining an Optimal Biologic Therapy
EP: 5.Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
EP: 6.Future Predictions for Intravenous and Subcutaneous Biologics
EP: 7.Overall Experience With Intravenous Biologics
EP: 8.Clinical Insights With Subcutaneous Biologics
EP: 9.Innovations Associated With IV Biologics
EP: 10.Exciting Developments With Subcutaneous Biologics
EP: 11.Positioning Intravenous and Subcutaneous Biologics
EP: 12.Adherence With Intravenous Biologics
Video content above is prompted by the following:
- How long have you been using IV biologics in your practice, for which indications, and what has your overall experience been like?
- How long have you been using subcutaneous biologics in your practice, for which indications, and what has your overall experience been like?
Recent Videos
Related Content
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021Article
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
